Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Synthetic cannabidiol - Benuvia Therapeutics/Radius Health

Next Previous
Drug Profile

Synthetic cannabidiol - Benuvia Therapeutics/Radius Health

Alternative Names: Pharmaceutical cannabidiol (CBD) - Benuvia Therapeutics/Radius Health; RAD-011

Latest Information Update: 12 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator INSYS Therapeutics, Inc
  • Developer Benuvia Therapeutics; California Pacific Medical Center; INSYS Therapeutics, Inc; Radius Health Inc.; The University of Montreal Hospital Research Center; University of Chicago
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
  • Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Absence epilepsy; Dravet syndrome; Lennox-Gastaut syndrome; Infantile spasms; Glioblastoma; Glioma; Prader-Willi syndrome; Schizophrenia
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Prader-Willi syndrome
  • Preclinical Endocrine disorders
  • Discontinued Dravet syndrome; Epilepsy; Glioblastoma; Infantile spasms; Lennox-Gastaut syndrome; Pain; Peripheral nervous system diseases; Substance-related disorders

Most Recent Events

  • 07 Dec 2022 Radius Pharmaceuticals terminates phase-II/III clinical trials in Prader-Willi syndrome (In adolescents, In children, In the elderly, In adults) in US, Spain and Sweden due to change in corporate priorities (PO) (NCT05098509)
  • 06 Oct 2022 Radius Pharmaceuticals withdraws prior to enrollment a phase III trial for Prader-Willi Syndrome (In adolescents, In adults, In children, In the elderly) (PO) (NCT05387798)
  • 22 Aug 2022 Radius Health plans a phase III trial for Angelman syndrome in USA (PO) in Q4 of 2022 (Radius Health pipeline, August 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top